R Jakesz

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. doi request reprint Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group
    Peter C Dubsky
    Medical University of Vienna, Austria
    J Clin Oncol 30:722-8. 2012
  2. ncbi request reprint Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
    Raimund Jakesz
    Department of Surgery, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    J Natl Cancer Inst 99:1845-53. 2007
  3. ncbi request reprint Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    Raimund Jakesz
    Austrian Breast and Colorectal Cancer Study Group ABCSG, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Lancet 366:455-62. 2005
  4. ncbi request reprint An update on ovarian suppression/ablation
    R Jakesz
    Division of General Surgery, Vienna Medical School, Vienna, Austria
    Int J Gynecol Cancer 16:511-4. 2006
  5. ncbi request reprint The adjuvant endocrine treatment revolution: focus on anastrozole
    Raimund Jakesz
    Vienna Medical School, Division of General Surgery, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Expert Opin Drug Metab Toxicol 2:301-12. 2006
  6. ncbi request reprint Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
    R Jakesz
    Department of Surgery, Internal Medicine, and Gynecology and Obstetrics, University of Vienna, Austria
    J Clin Oncol 17:1701-9. 1999
  7. doi request reprint Objectively measured breast symmetry has no influence on quality of life in breast cancer patients
    R Exner
    Department of Surgery, Medical University Vienna, Breast Health Care Center, Waehringer Guertel 18 20 Vienna, Austria
    Eur J Surg Oncol 38:130-6. 2012
  8. doi request reprint Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer
    O Riedl
    LKH Krems, Department of Surgery, Austria
    Eur J Surg Oncol 35:264-70. 2009
  9. doi request reprint HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
    S F Schoppmann
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Ann Oncol 21:955-60. 2010
  10. doi request reprint Breast cancer chemoprevention - a vision not yet realized
    P Blaha
    Department of Surgery, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
    Eur J Cancer Care (Engl) 18:438-46. 2009

Detail Information

Publications100

  1. doi request reprint Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group
    Peter C Dubsky
    Medical University of Vienna, Austria
    J Clin Oncol 30:722-8. 2012
    ....
  2. ncbi request reprint Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
    Raimund Jakesz
    Department of Surgery, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    J Natl Cancer Inst 99:1845-53. 2007
    ..We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy...
  3. ncbi request reprint Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    Raimund Jakesz
    Austrian Breast and Colorectal Cancer Study Group ABCSG, Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Lancet 366:455-62. 2005
    ..We investigate whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole...
  4. ncbi request reprint An update on ovarian suppression/ablation
    R Jakesz
    Division of General Surgery, Vienna Medical School, Vienna, Austria
    Int J Gynecol Cancer 16:511-4. 2006
    ..Published reports have demonstrated that ovarian suppression is a safe means of reducing risk of recurrence in estrogen receptor-positive women and underlined its use as a competitive alternative to chemotherapy in this patient subset...
  5. ncbi request reprint The adjuvant endocrine treatment revolution: focus on anastrozole
    Raimund Jakesz
    Vienna Medical School, Division of General Surgery, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Expert Opin Drug Metab Toxicol 2:301-12. 2006
    ..The use of anastrozole is now widely accepted in advanced breast cancer and its superior efficacy and tolerability to tamoxifen has recently been demonstrated in early breast cancer...
  6. ncbi request reprint Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
    R Jakesz
    Department of Surgery, Internal Medicine, and Gynecology and Obstetrics, University of Vienna, Austria
    J Clin Oncol 17:1701-9. 1999
    ..To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival...
  7. doi request reprint Objectively measured breast symmetry has no influence on quality of life in breast cancer patients
    R Exner
    Department of Surgery, Medical University Vienna, Breast Health Care Center, Waehringer Guertel 18 20 Vienna, Austria
    Eur J Surg Oncol 38:130-6. 2012
    ..This study investigates how quality of life (QoL) of breast cancer patients is related to breast symmetry...
  8. doi request reprint Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer
    O Riedl
    LKH Krems, Department of Surgery, Austria
    Eur J Surg Oncol 35:264-70. 2009
    ....
  9. doi request reprint HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
    S F Schoppmann
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Ann Oncol 21:955-60. 2010
    ..In addition to blocking of HER2/neu, tyrosine kinase significantly decreased VEGF-C expression in vitro...
  10. doi request reprint Breast cancer chemoprevention - a vision not yet realized
    P Blaha
    Department of Surgery, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
    Eur J Cancer Care (Engl) 18:438-46. 2009
    ..With promising results in adjuvant settings, aromatase inhibitors may deliver better prevention treatment options in the future, nevertheless, more research is needed to reliably predict risk on an individual basis in the future...
  11. doi request reprint Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
    Michael Gnant
    Department of Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria
    Lancet Oncol 9:840-9. 2008
    ..The aim of this substudy is to gain insight into bone health in this setting...
  12. ncbi request reprint Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas
    Raimund Jakesz
    Department of Surgery, Vienna University, Vienna General Hospital, Austria
    J Clin Oncol 20:4621-7. 2002
    ..The purpose of Austrian Breast and Colorectal Cancer Study Group Trial 5 was to compare the efficacy of a combination endocrine treatment with standard chemotherapy...
  13. ncbi request reprint Video assistance reduces complication rate of thoracoscopic sympathicotomy for hyperhidrosis
    J Zacherl
    University Clinic of Surgery, Vienna General Hospital, Austria
    Ann Thorac Surg 68:1177-81. 1999
    ..However, up to 8% of patients experience Horner's syndrome, and about 50% show compensatory sweating. This study evaluates the role of video assistance in thoracoscopic sympathicotomy for primary hyperhidrosis of the upper limb...
  14. doi request reprint Recent developments in breast-conserving surgery for breast cancer patients
    F Fitzal
    Department of Surgery, Medical University Vienna, Vienna, Austria
    Langenbecks Arch Surg 394:591-609. 2009
    ..This invited review deals with the latest knowledge regarding breast conserving therapy in breast conserving patients...
  15. ncbi request reprint Efficacy and safety of thoracoscopic sympathicotomy for hyperhidrosis of the upper limb. Results of 734 sympathicotomies
    C H Neumayer
    , Allgemeines Krankenhaus der Stadt Wien, , Vienna, Austria
    Ann Chir Gynaecol 90:195-9. 2001
    ..7). CONCLUSIONS: We observed a significant decrease of the incidence of complete or incomplete Horner's syndrome and gustatory sweating when the procedure was guided by video-imaging while success rate was similar when compared with CTS...
  16. pmc The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
    M Gnant
    Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
    Br J Cancer 109:589-96. 2013
    ..07).Conclusion:Body mass index may be used to predict outcome benefit of extended AI treatment in patients with receptor-positive breast cancer. ..
  17. pmc Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
    G Pfeiler
    Division of Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
    Br J Cancer 108:1408-14. 2013
    ..We investigated the impact of BMI on the efficacy of single tamoxifen and tamoxifen plus an aromatase inhibitor in the well-defined prospective study population of the ABCSG-06 trial...
  18. doi request reprint Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study
    F Fitzal
    Department of Surgery, Breast Health Center, Medical University Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Breast Cancer Res Treat 127:121-8. 2011
    ..These patients, however, should not be treated with breast conservation in the absence of any proven response after nCT...
  19. ncbi request reprint Prognostic relevance of three histological grading methods in breast cancer
    L Latinovic
    Department of Clinical Pathology, University of Vienna, Vienna, Austria
    Int J Oncol 19:1271-7. 2001
    ..Also, we could demonstrate that histological grading in needle biopsies is reliable enough to allow a preoperative risk estimation...
  20. ncbi request reprint Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Vienna, Austria
    Int J Cancer 104:677-82. 2003
    ..Our results also suggest that due to the apparent interaction of Id-1 with the steroid-receptor system in breast cancer, hormonal therapies might influence Id-1 expression and its impact on clinical outcome...
  21. ncbi request reprint Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy
    Gudrun Pohl
    Department of Internal Medicine 1, Division of Oncology, University Hospital, Vienna, Austria
    Breast Cancer Res Treat 78:97-103. 2003
    ....
  22. ncbi request reprint Improved quality of life after sympathetic block for upper limb hyperhidrosis
    P Panhofer
    Department of General Surgery, University Clinic of Surgery, Medical University of Vienna, Austria
    Br J Surg 93:582-6. 2006
    ..The aim of the study was to assess two disease-specific quality of life (QoL) instruments after limited endoscopic thoracic sympathetic block (TS) at T4 for upper limb hyperhidrosis...
  23. ncbi request reprint Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis
    G Schueller
    Department of Surgery, University Hospital Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    Anticancer Res 21:295-300. 2001
    ..We conclude that HSP expression in HepG2 cells can be enhanced by heat shock treatment in vitro. We suggest that this mechanism can be exploited in increasing tumor immunogenicity...
  24. ncbi request reprint Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy
    Margaretha Rudas
    Department of Pathology, University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 81:149-57. 2003
    ..Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression...
  25. ncbi request reprint Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience
    G G Steger
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18 20 Währinger Gürtel, A 1090 Vienna, Austria
    Eur J Cancer 41:2655-61. 2005
    ..Fulvestrant was well tolerated; six patients experienced adverse events (all grade I/II). These data demonstrate that fulvestrant is an effective and well-tolerated therapy for patients with ABC progressing on prior therapies...
  26. ncbi request reprint Selective resection of colorectal liver metastases
    D Tamandl
    Department of Surgery, Hepatobiliary Service, Vienna Medical University, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Eur J Surg Oncol 33:174-82. 2007
    ..Safety of liver surgery for colorectal cancer liver metastases after neoadjuvant chemotherapy has to be re-evaluated...
  27. ncbi request reprint Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Wien Klin Wochenschr 116:26-31. 2004
    ..Since core needle biopsy is increasingly used for the diagnosis of breast cancer, the purpose of this study was to assess the reliability of HER2/neu evaluation using this technique in patients with primary breast cancer...
  28. ncbi request reprint Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment
    Rupert Bartsch
    First Department of Medicine, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:4435-9. 2007
    ..In this study, we evaluated factors that are potentially predictive of response and time to progression in patients treated with fulvestrant...
  29. ncbi request reprint Survival after surgical treatment of breast cancer
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Langenbecks Arch Surg 389:75-82. 2004
    ..e. complete resection with tumour-free margins. Type and extent of breast surgery is dependent on tumour stage; beyond that and even more importantly, prognosis of an individual patient depends upon its stage at diagnosis...
  30. ncbi request reprint Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Cancer 98:2547-53. 2003
    ..The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status...
  31. pmc Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group
    Raimund Jakesz
    Department of Surgery, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Surg 237:556-64. 2003
    ..To confirm evidence that breast-conserving treatment (BCT) does not impair the prognosis in breast cancer patients as compared to mastectomy and to argue that it be regarded as the treatment of choice in stage I and II disease...
  32. ncbi request reprint Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer
    Monika Schindl
    Institute of Clinical Pathology, Department of Surgery, University of Vienna Medical School, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Clin Cancer Res 8:1831-7. 2002
    ..The aim of this study was to determine the prognostic influence of HIF-1alpha expression in patients with advanced-stage breast cancer, evident by positive lymph nodes...
  33. doi request reprint Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma
    D Tamandl
    Departments of Surgery, Medical University of Vienna, Vienna, Austria
    Br J Surg 96:919-25. 2009
    ..Intrahepatic cholangiocarcinoma (ICC) is rare but its incidence is rising worldwide. The value of lymph node dissection for ICC is under discussion; the current staging systems do not differentiate between numbers of involved nodes...
  34. ncbi request reprint Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer
    E Janschek
    Department of Surgery, University of Vienna, Austria
    Breast Cancer Res Treat 67:1-8. 2001
    ..We could also demonstrate that contralateral breast cancer spread does occur. Standard pathological assessment allowed a firm diagnosis only in the presence of different histological types...
  35. ncbi request reprint Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy
    S Taucher
    Department of Surgery, Vienna University Medical School, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Endocr Relat Cancer 10:91-8. 2003
    ..Preoperative cytotoxic chemotherapy induced a significant extent of variation in the steroid receptor expression of breast cancer cells...
  36. ncbi request reprint Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Breast Cancer Res Treat 82:207-13. 2003
    ....
  37. ncbi request reprint Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, University of Vienna, Vienna, Austria
    Anticancer Drugs 16:441-5. 2005
    ..We conclude that outpatient TEX+P is safe in the neoadjuvant treatment of patients with primary breast cancer. Thus, this regimen can be considered for further clinical trials...
  38. ncbi request reprint Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients
    Florian Fitzal
    Department of Surgery, General Hospital, University Vienna, Waehringer Guertd 18 20, 1090 Vienna, Austria
    Breast Cancer Res Treat 97:9-15. 2006
    ..The impact of this observation on local recurrence and overall survival rate is, however, not fully investigated...
  39. doi request reprint New epidemiological aspects of patients with severe hyperhidrosis presenting for sympathetic surgery
    D Karimian-Teherani
    Division of General Dermatology, Medical University of Vienna, Vienna, Austria
    J Eur Acad Dermatol Venereol 23:651-5. 2009
    ..Epidemiological data on individuals suffering from severe primary hyperhidrosis are scarce...
  40. ncbi request reprint An oncoplastic procedure for central and medio-cranial breast cancer
    F Fitzal
    Department of Surgery, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Eur J Surg Oncol 33:1158-63. 2007
    ..The technique may be used for breast cancer at various locations and reduces scar visibility and morbidity...
  41. ncbi request reprint Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Waehringer, Vienna, Austria
    Breast Cancer Res Treat 99:135-41. 2006
    ....
  42. ncbi request reprint Predictors for complications after loop stoma closure in patients with rectal cancer
    Herwig Pokorny
    Department of Surgery, University Hospital of Vienna, 21A Währinger Gürtel 18 20, 1090, Vienna, Austria
    World J Surg 30:1488-93. 2006
    ..This unmatched case control study was undertaken to evaluate factors contributing to surgery-related complications of loop stoma closure in patients with rectal cancer...
  43. ncbi request reprint Mortality and complications after stoma closure
    Herwig Pokorny
    Department of Surgery, University Hospital of Vienna, 21 A Wāhringer Gürtel 18 20, 1090 Vienna, Austria
    Arch Surg 140:956-60, discussion 960. 2005
    ..This study was undertaken to evaluate factors contributing to hospital mortality and complications of stoma closure...
  44. doi request reprint Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy
    Martin Filipits
    Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Clin Cancer Res 15:5888-94. 2009
    ..The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy...
  45. doi request reprint Breast-conserving therapy for centrally located breast cancer
    Florian Fitzal
    Department of Surgery, Medical University of Vienna, Austria
    Ann Surg 247:470-6. 2008
    ..To analyze whether breast-conserving therapy (BCT) may be an oncologically safe approach and result in a good cosmesis in patients with centrally located breast cancer (CLBC)...
  46. ncbi request reprint Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
    Catharina Wenzel
    Department of Internal Medicine I, Division of Clinical Oncology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Breast Cancer Res Treat 104:109-14. 2007
    ..We questioned the impact of histologic type invasive ductal carcinoma (IDC) versus invasive lobular carcinoma (ILC) on response to primary chemotherapy...
  47. doi request reprint Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis
    Peter Panhofer
    Department of General Surgery, E21 A, University Clinic of Surgery, Medical University of Vienna, Vienna, Austria
    Langenbecks Arch Surg 394:265-71. 2009
    ..The aim was to find significant risk factors for mortality and tertiary peritonitis including the Mannheim Peritonitis Index (MPI), the Acute Physiology and Chronic Health Evaluation (APACHE) II score, and a sumscore of both...
  48. doi request reprint Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy
    Peter Dubsky
    Department of Surgery, Medical University Vienna, Vienna, Austria
    Clin Cancer Res 14:2082-7. 2008
    ....
  49. ncbi request reprint Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
    Günther G Steger
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2012-8. 2007
    ..This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate...
  50. ncbi request reprint Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients
    Florian Fitzal
    Department of Surgery, Medical University Vienna, Waehringer Guertel 18 20, 1080 Vienna, Austria
    Breast Cancer Res Treat 103:45-52. 2007
    ..In special cancer centers up to 90% of patients are treated with BCT. T3/T4 breast cancer is one of the few contraindications for BCT. However, retrospective data suggest that BCT may be eligible in selected cases of T3/T4 breast cancer...
  51. ncbi request reprint Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer
    Richard Potter
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Int J Radiat Oncol Biol Phys 68:334-40. 2007
    ..In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial...
  52. doi request reprint Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    Michael Gnant
    Medical University of Vienna, Austria
    N Engl J Med 360:679-91. 2009
    ..Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties...
  53. ncbi request reprint Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group
    Michael F X Gnant
    Department of Surgery, General Hospital, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:820-8. 2007
    ..This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients...
  54. doi request reprint Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Michael Gnant
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Clin Breast Cancer 9:S18-27. 2009
    ..Results from ongoing studies are expected to further elucidate the benefits of bisphosphonates in maintaining bone health and improving clinical outcomes in patients with breast cancer...
  55. ncbi request reprint VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival
    Sebastian F Schoppmann
    Department of Surgery, University of Vienna, Austria
    Surgery 139:839-46. 2006
    ..Aim of this study was to clear the role of VEGF-C/D expressing TAMs in invasive breast cancer...
  56. ncbi request reprint [Treatment of achalasia]
    Enrico P Cosentini
    Klinische Abteilung für Allgemeinchirurgie, Universitatsklinik fur Chirurgie, Wien, Osterreich
    Wien Klin Wochenschr 116:296-304. 2004
    ..This article aims to provide an overview of the development of the conservative and surgical treatment of achalasia...
  57. ncbi request reprint Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer
    Wolfgang J Kostler
    Clinical Division of Oncology, Department of Medicine I, University Hospital of Vienna, Vienna, Austria
    Anticancer Res 24:1127-30. 2004
    ....
  58. ncbi request reprint Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen
    Thomas Bachleitner-Hofmann
    Department of Surgery, University of Vienna, A 1090 Vienna, Austria
    Clin Cancer Res 8:3427-32. 2002
    ....
  59. pmc Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
    Sebastian F Schoppmann
    Department of Surgery, Medical University of Vienna, Austria
    Ann Surg 240:306-12. 2004
    ..The aim of this study was to investigate the prognostic relevance of lymphangiogenesis and lymphovascular invasion in a large cohort of breast cancer patients...
  60. ncbi request reprint Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group
    Martin Filipits
    Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 23:1161-8. 2005
    ..Therefore, we determined the impact of MRP1 expression on the clinical outcome of adjuvant therapy in patients with early-stage breast cancer...
  61. ncbi request reprint Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer
    Alexandra Resch
    Department of Radiotherapy and Radiobiology, Vienna University, Medical School, General Hospital of Vienna, Währinger Gürtel 18 22, Vienna, Austria
    Radiother Oncol 63:47-58. 2002
    ..In this retrospective study a large cohort of 410 women with early breast cancer treated with BCT including an interstitial brachytherapy (BT) boost is evaluated after a long follow-up period...
  62. ncbi request reprint How to pass on expertise: pancreatoduodenectomy at a teaching hospital
    Peter Wamser
    Surgical Department, Division of General Surgery, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    World J Surg 26:1458-62. 2002
    ..Under direct supervision of an experienced surgeon PD can be performed safely as a teaching operation. A caseload of at least one resection per year seems necessary for consistently good results...
  63. ncbi request reprint Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells
    Peter C Dubsky
    Vienna Medical School, Department of Surgery, A 1090 Wien, Wahringer Gurtel 18 20, Austria
    Clin Chim Acta 364:139-47. 2006
    ..Recent evidence suggests MPA to affect antigen-presenting cells...
  64. doi request reprint Long-term outcomes after endothoracic sympathetic block at the T4 ganglion for upper limb hyperhidrosis
    P Panhofer
    Departments of General Surgery, University Clinic of Surgery, Medical University of Vienna, Vienna, Austria
    Br J Surg 100:1471-7. 2013
    ..The aim of this study was to evaluate long-term results, quality of life, satisfaction and compensatory sweating after endothoracic sympathetic block at T4 (ESB4)...
  65. ncbi request reprint Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer
    R Jakesz
    The Department of Surgery, University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Eur J Cancer 38:327-32. 2002
    ..We argue that selection of adjuvant systemic therapy for premenopausal breast cancer patients be increasingly guided by knowledge of the steroid hormone receptor levels...
  66. doi request reprint Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases
    Dietmar Tamandl
    Department of Surgery, Medical University of Vienna, Vienna, Austria
    Surgery 143:648-57. 2008
    ..We investigated the value of preoperative staging on detection of additional resectable hepatic lesions in metastatic colorectal cancer patients...
  67. ncbi request reprint Dendritic cell vaccination in medullary thyroid carcinoma
    Anton Stift
    Department of Surgery, University of Vienna, Medical School, Vienna, Austria
    Clin Cancer Res 10:2944-53. 2004
    ..Palliative treatment options show no significant benefit. A promising treatment approach for human cancer is based on the vaccination of autologous dendritic cells (DCs)...
  68. ncbi request reprint Impact of pretreatment thrombocytosis on survival in primary breast cancer
    Susanne Taucher
    Department of Surgery, University of Vienna Medical School, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Thromb Haemost 89:1098-106. 2003
    ..1355). In our retrospective study, elevated platelet counts at time of diagnosis were associated with poor prognosis in breast cancer. We hypothesize that platelets may contribute to the pathophysiology of hematogenous metastasis...
  69. pmc Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II)
    J Widder
    Department of Radiotherapy and Radiobiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Br J Cancer 92:1209-14. 2005
    ..Bowel function was satisfactory after more than 5 years. Local control in primarily resectable rectal cancer after 10 x 2.5 Gy is excellent, warranting further evaluation of this treatment...
  70. ncbi request reprint Limited endoscopic thoracic sympathetic block for hyperhidrosis of the upper limb: reduction of compensatory sweating by clipping T4
    C Neumayer
    Department of General Surgery, University Clinic of Surgery, Vienna General Hospital, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Surg Endosc 18:152-6. 2004
    ..We present our experience and clinical results using this method, with emphasis on patients' quality of life...
  71. ncbi request reprint The use of a breast symmetry index for objective evaluation of breast cosmesis
    F Fitzal
    Department of Surgery, Medical University Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Breast 16:429-35. 2007
    ..9; p<0.05) and the BSI was able to significantly differentiate between good and bad cosmesis (BSI values from 0%d to 30%d is good, BSI>30%d is bad cosmesis). Thus the BSI may be used for clinical studies...
  72. ncbi request reprint Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma
    Johannes Zacherl
    Department of Allgemeinchirurgie, Universitätsklinik für Chirurgie and Universität Wien, Vienna, Austria
    J Gastrointest Surg 6:682-9. 2002
    ..On the other hand, curative resection of metachronous liver metastases may allow long-term survival in selected patients...
  73. ncbi request reprint HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer
    Gerhild Fabjani
    Department of Obstetrics and Gynecology, General Hospital of Vienna, Molecular Oncology Group, Waehringer Guertel 18 20, 5Q, A 1090 Vienna, Austria
    Oncol Rep 14:737-41. 2005
    ..0056). Although, HMGA2 obviously contributes to invasion it is not a specific marker for the detection of circulating tumor cells in peripheral blood...
  74. ncbi request reprint Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy
    Christine Brostjan
    Department of General Surgery, General Hospital, University of Vienna, Vienna, Austria
    Cancer 98:2291-301. 2003
    ....
  75. ncbi request reprint Dendritic cell-based vaccination in solid cancer
    A Stift
    Department of Surgery, University of Vienna Medical School, Vienna, Austria
    J Clin Oncol 21:135-42. 2003
    ..In this study, cancer patients with advanced disease that lacks defined tumor antigens were vaccinated with tumor lysate-pulsed DCs...
  76. ncbi request reprint A genetically engineered influenza A virus with ras-dependent oncolytic properties
    M Bergmann
    Department of Surgery, University of Vienna Medical School, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Cancer Res 61:8188-93. 2001
    ....
  77. ncbi request reprint Teaching laparoscopic cholecystectomy: do beginners adversely affect the outcome of the operation?
    M Imhof
    University Clinic of Surgery, University of Vienna, Vienna General Hospital, Vienna, Austria
    Eur J Surg 168:470-4. 2002
    ..To evaluate the safety of elective laparoscopic cholecystectomy (LC) as a supervised teaching procedure...
  78. ncbi request reprint In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
    Anton Stift
    Department of Surgery, University of Vienna Medical School, A 1090 Vienna, Austria
    Int J Oncol 22:651-6. 2003
    ..Even though this study was confined to a single patient, the data might open a door for novel immunotherapeutical strategies...
  79. ncbi request reprint Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene
    Susanne Taucher
    Department of Surgery, Medical School, Vienna University, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Langenbecks Arch Surg 388:3-8. 2003
    ..Despite the reduction in the risk of developing breast cancer, prophylactic mastectomy often leads to significant physical and psychological sequelae...
  80. ncbi request reprint Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity?
    Felix B Langer
    Department of Surgery, Division of General Surgery, Medical University of Vienna, Vienna, Austria
    Obes Surg 16:166-71. 2006
    ..The efficacy of laparoscopic sleeve gastrectomy (LSG) for morbidly obese patients with a BMI of <50 kg/m2 and the incidence of gastric dilatation following LSG have not yet been investigated...
  81. pmc TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer
    Daniela Kandioler
    Department of Surgery, University of Vienna, Vienna, Austria
    Ann Surg 235:493-8. 2002
    ..To evaluate and compare the predictive power of p53 gene analysis versus p53 immunohistochemical staining in terms of response to preoperative short-term radiotherapy using 25 Gy in operable rectal cancer...
  82. ncbi request reprint Retroviral targeting of proliferating endothelial cells
    Alexander Gornikiewicz
    Department of Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    Acta Biochim Pol 52:731-5. 2005
    ..However, while being selective for proliferating human endothelial cells, the recombinant retroviral particles displayed low transduction efficiencies and thus have to be further improved...
  83. ncbi request reprint Current value of intraoperative sonography during surgery for hepatic neoplasms
    Johannes Zacherl
    Department of Surgery, Division of General Surgery, AKH 21 A, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    World J Surg 26:550-4. 2002
    ....
  84. ncbi request reprint Experience with limited endoscopic thoracic sympathetic block for hyperhidrosis and facial blushing
    Christoph Neumayer
    Dept of General Surgery, University Clinic of Surgery, Vienna General Hospital AKH E 21 A, Wahringer Gurtel 18 20, Vienna, 1090, Austria
    Clin Auton Res 13:I52-7. 2003
    ..3% and in the ESB3 group 13.9% were partly satisfied. Limited sympathetic surgery offers comparably high success and satisfaction rates along with a low rate of side effects...
  85. ncbi request reprint Surgical treatment of severe acute pancreatitis: timing of operation is crucial for survival
    Peter Götzinger
    Department of Surgery, University of Vienna, Vienna, Austria
    Surg Infect (Larchmt) 4:205-11. 2003
    ..In patients operated on for severe acute pancreatitis (SAP) the impact of the timing of operation on outcome is controversial...
  86. ncbi request reprint Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria
    Anticancer Drugs 13:67-74. 2002
    ..Thus, this regimen can be considered for further clinical trials...
  87. ncbi request reprint Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer
    Catharina Wenzel
    Department of Internal Medicine I Division of Oncology, University Hospital of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Cancer Chemother Pharmacol 50:155-9. 2002
    ....
  88. ncbi request reprint Preoperative second-line chemotherapy induces objective responses in primary breast cancer
    Catharina Wenzel
    Division of Oncology, Department of Internal Medicine I, University Hospital of Vienna, Austria
    Wien Klin Wochenschr 117:48-52. 2005
    ..We questioned this hypothesis and treated 13 patients who did not respond to preoperative anthracycline-containing first-line treatment...
  89. ncbi request reprint Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer
    Peter C Dubsky
    Department of General Surgery, University of Vienna, Austria
    Clin Breast Cancer 3:65-72. 2002
    ..Future studies should focus on unveiling the young age surrogate in order to improve treatment and prognosis...
  90. ncbi request reprint [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells]
    Raimund Jakesz
    MMW Fortschr Med 147:8. 2005
  91. ncbi request reprint Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
    Catharina Wenzel
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    J Cancer Res Clin Oncol 130:400-4. 2004
    ..We conducted a pilot study of preoperative epidoxorubicin and docetaxel plus trastuzumab in outpatient patients suffering from breast cancer...
  92. doi request reprint Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
    Prudence Francis
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
    J Natl Cancer Inst 100:121-33. 2008
    ..The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel...
  93. doi request reprint Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
    Margaretha Rudas
    Department of Pathology, Medical University of Vienna, Austria
    Clin Cancer Res 14:1767-74. 2008
    ..The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy...
  94. ncbi request reprint Treatment of breast cancer in countries with limited resources
    Robert W Carlson
    Department of Medicine, Stanford University, Stanford, California 94305, USA
    Breast J 9:S67-74. 2003
    ..Efforts to reduce the number of breast cancers diagnosed at an advanced stage thus have the potential to improve rates of survival while decreasing the use of limited resources...
  95. ncbi request reprint Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis
    Walter Jonat
    University of Kiel, Germany
    Lancet Oncol 7:991-6. 2006
    ..We aimed to investigate whether switching treatment of postmenopausal women with such breast cancer to anastrozole after 2-3 years of tamoxifen would be more effective than continuing on tamoxifen for a total of 5 years...
  96. ncbi request reprint Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6
    Marianne Schmid
    Medical Department, Graz University, and Second Department of Surgery, Graz Hospital, Graz, Austria
    J Clin Oncol 21:984-90. 2003
    ..To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer...
  97. ncbi request reprint High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin
    Gudrun Pohl
    Department of Medicine I, Clinical Division of Oncology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 21:3594-600. 2003
    ..To determine the predictive value of p27Kip1 in premenopausal women with early-stage hormone receptor-positive breast cancer...
  98. ncbi request reprint Survival of women with breast cancer in Austria by age, stage and period of diagnosis
    Christian Vutuc
    Division of Epidemiology, Institute for Cancer Research, Medical School, University of Vienna, Austria
    Wien Klin Wochenschr 114:438-42. 2002
    ..To investigate survival of breast cancer patients by 1) age, 2) tumor stage and 3) period of diagnosis, also to determine the contribution of improvements in treatment and opportunistic mammography screening in Austria...
  99. ncbi request reprint Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells
    Gerd Schueller
    Department of Radiology, University Hospital of Vienna Medical School, A 1090 Vienna, Austria
    Int J Oncol 22:1397-402. 2003
    ..The improved cellular immune response can be related to enhanced expression of HSP 70 and 90 in HepG2 cells upon hyperthermia...
  100. ncbi request reprint Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus
    Johannes Zacherl
    Universitatsklinik fur Chirurgie, Klinische Abteilung für Allgemeinchirurgie, Allgemeines Krankenhaus der Stadt Wien, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    World J Surg 27:1067-74. 2003
    ..Neoadjuvant treatment of adenocarcinoma of the esophagus, as a consequence, is currently not the standard treatment and should be performed only within controlled clinical trials...